basiliximab Injection

Brand(s)
Simulect
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Novartis Pharmaceuticals Corporation (2009-10-05)
Oldest Current Product
1998-05-12
License(s)
BLA
RxNORM
INJECTION\BASILIXIMAB
SPL Active
INTRAVENOUS\INJECTION, POWDER, FOR SOLUTION\BASILIXIMAB
SPL Moiety
INTRAVENOUS\INJECTION, POWDER, FOR SOLUTION\BASILIXIMAB

product(s) by strength(s)

basiliximab 10 mg injection

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1000780393SimulectBLANovartis Pharmaceuticals Corporation1998-05-12BASILIXIMABINTRAVENOUSINJECTION, POWDER, FOR SOLUTION1037641af01887-b69d-444b-91ed-ebfe12784440

basiliximab 20 mg injection

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1000780331SimulectBLANovartis Pharmaceuticals Corporation1998-05-12BASILIXIMABINTRAVENOUSINJECTION, POWDER, FOR SOLUTION1037641af01887-b69d-444b-91ed-ebfe12784440

application(s)

#idtitleapprovedtradenamesfda division
1103764basiliximab Application1998-05-12SimulectCDER

spl(s)

#idtitlecategorytypelabelerlast updateversionproduct(s)
11af01887-b69d-444b-91ed-ebfe12784440 (view SPL)T2005-28 2027722 Simulect (basiliximab) For Injection Rx only Prescribing InformationprescriptionHuman PrescriptionNovartis Pharmaceuticals Corporation2009-10-053000780331, 000780393

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII